{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:29:43Z","timestamp":1785814183190,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007546","name":"Agence Nationale de S\u00e9curit\u00e9 Sanitaire de l\u2019Alimentation, de l\u2019Environnement et du Travail","doi-asserted-by":"publisher","award":["21E1168\/00061963"],"award-info":[{"award-number":["21E1168\/00061963"]}],"id":[{"id":"10.13039\/501100007546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018696","name":"R\u00e9gion Normandie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.virusres.2024.199503","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:27:59Z","timestamp":1733938079000},"page":"199503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy assessment of antiretroviral drugs against equine infectious anemia virus in vitro"],"prefix":"10.1016","volume":"350","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-4664","authenticated-orcid":false,"given":"C\u00e9cile","family":"Schimmich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Vabret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9637-7085","authenticated-orcid":false,"given":"Jos\u00e9-Carlos","family":"Valle-Casuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.virusres.2024.199503_bib0001","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/mol.61.2.400","article-title":"Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance\/sensitivity to non-nucleoside reverse transcriptase inhibitors","volume":"61","author":"Auwerx","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"4599","key":"10.1016\/j.virusres.2024.199503_bib0002","first-page":"868","article-title":"Isolation of a T-Lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.virusres.2024.199503_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(01)00190-5","article-title":"Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication","volume":"53","author":"Bisset","year":"2002","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.virusres.2024.199503_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1099\/0022-1317-77-3-419","article-title":"Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug","volume":"77","author":"Borman","year":"1996","journal-title":"J. General Virol."},{"issue":"8","key":"10.1016\/j.virusres.2024.199503_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1099\/0022-1317-83-8-1809","article-title":"Cell surface receptors, virus entry and tropism of primate lentiviruses","volume":"83","author":"Clapham","year":"2002","journal-title":"J. Gener. Virol."},{"issue":"35","key":"10.1016\/j.virusres.2024.199503_bib0006","doi-asserted-by":"crossref","first-page":"13044","DOI":"10.1073\/pnas.0404006101","article-title":"Feline immunodeficiency virus targets activated CD4 T cells by using CD134 as a binding receptor","volume":"101","author":"De Parseval","year":"2004","journal-title":"Proceed. Nation. Acad. Sci."},{"issue":"17","key":"10.1016\/j.virusres.2024.199503_bib0007","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.virusres.2024.199503_bib0008","article-title":"Pharmacological outlook of lenacapavir: a novel first-in-class long-acting HIV-1 capsid inhibitor","volume":"31","author":"Di Perri","year":"2023","journal-title":"Infezioni in Medicina"},{"issue":"1\u20132","key":"10.1016\/j.virusres.2024.199503_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vetimm.2008.01.007","article-title":"Molecular mechanisms of FIV infection","volume":"123","author":"Elder","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"41","key":"10.1016\/j.virusres.2024.199503_bib0010","doi-asserted-by":"crossref","first-page":"15137","DOI":"10.1074\/jbc.REV119.006901","article-title":"Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition","volume":"294","author":"Engelman","year":"2019","journal-title":"J. Biolog. Chem."},{"issue":"1","key":"10.1016\/j.virusres.2024.199503_bib0011","first-page":"5","article-title":"HIV virology and pathogenetic mechanisms of infection: a brief overview","volume":"46","author":"Fanales-Belasio","year":"2010","journal-title":"Annali Dell'Istituto Superiore Di Sanita"},{"key":"10.1016\/j.virusres.2024.199503_bib0012","unstructured":"Gaudaire, Delphine, Aur\u00e9lie Merlin, Jackie Tapprest, Marie Delerue, Marie Grandcollot-Chabot, and Aymeric HANS. 2019. \u2018Deux nouveaux foyers d'an\u00e9mie infectieuse des equid\u00e9s en dordogne et en haute-savoie d\u00e9clar\u00e9s \u00e0 l'automne 2019, https:\/\/Www.Plateforme-Esa.Fr\/Fr\/Deux-Nouveaux-Foyers-Danemie-Infectieuse-Des-Equides-En-Dordogne-et-En-Haute-Savoie-Declares, (Accessed Jul. 05 2024)\u2019, 2019. https:\/\/www.plateforme-esa.fr\/fr\/deux-nouveaux-foyers-danemie-infectieuse-des-equides-en-dordogne-et-en-haute-savoie-declares."},{"issue":"1\u201310","key":"10.1016\/j.virusres.2024.199503_bib0013","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1439-0442.1995.tb00392.x","article-title":"Long-term treatment of diseased, FIV-seropositive field cats with azidothymidine (AZT)","volume":"42","author":"Hart","year":"1995","journal-title":"J. Veterin. Med. Series A"},{"issue":"4","key":"10.1016\/j.virusres.2024.199503_bib0014","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/vetsci2040456","article-title":"Efficacy of antiviral drugs against feline immunodeficiency virus","volume":"2","author":"Hartmann","year":"2015","journal-title":"Vet. Sci."},{"issue":"1","key":"10.1016\/j.virusres.2024.199503_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2460\/javma.255.1.63","article-title":"Transmission of equine infectious anemia virus by Tabanus Fuscicostatus","volume":"168","author":"Hawkins","year":"1976","journal-title":"J. Am. Vet. Med. Assoc."},{"issue":"6","key":"10.1016\/j.virusres.2024.199503_bib0016","first-page":"411","article-title":"Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"issue":"3","key":"10.1016\/j.virusres.2024.199503_bib0017","first-page":"561","article-title":"Equine infectious anemia in 2014: live with it or eradicate it?","volume":"30","author":"Issel","year":"2014","journal-title":"Veterin. Clinics North America"},{"issue":"14","key":"10.1016\/j.virusres.2024.199503_bib0018","doi-asserted-by":"crossref","first-page":"8793","DOI":"10.1128\/JVI.79.14.8793-8801.2005","article-title":"Equine infectious anemia virus gag p9 function in early steps of virus infection and provirus production","volume":"79","author":"Jin","year":"2005","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virusres.2024.199503_bib0019","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/pro.5560071108","article-title":"Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV\u2019","volume":"7","author":"Kervinen","year":"1998","journal-title":"Protein Sci."},{"issue":"4","key":"10.1016\/j.virusres.2024.199503_bib0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2165\/00003495-198937040-00003","article-title":"Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy","volume":"37","author":"Langtry","year":"1989","journal-title":"Drugs"},{"issue":"4899","key":"10.1016\/j.virusres.2024.199503_bib0021","first-page":"1731","article-title":"HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy","volume":"243","author":"Larder","year":"1989","journal-title":"Science (1979)"},{"issue":"4","key":"10.1016\/j.virusres.2024.199503_bib0022","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1051\/vetres:2004020","article-title":"Equine infectious anemia virus (EIAV): what has HIV's country cousin got to tell us?","volume":"35","author":"Leroux","year":"2004","journal-title":"Vet. Res."},{"issue":"2","key":"10.1016\/j.virusres.2024.199503_bib0023","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.antiviral.2011.08.016","article-title":"An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern","volume":"92","author":"Lin","year":"2011","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.virusres.2024.199503_bib0024","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.virusres.2024.199503_bib0025","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/157016208785132527","article-title":"Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1","volume":"6","author":"Norelli","year":"2008","journal-title":"Curr. HIV Res."},{"issue":"13","key":"10.1016\/j.virusres.2024.199503_bib0026","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection\u2019","volume":"338","author":"Palella","year":"1998","journal-title":"England J. Med."},{"issue":"1","key":"10.1016\/j.virusres.2024.199503_bib0027","first-page":"44","article-title":"A brief history of antiretroviral therapy of HIV infection: success and challenges","volume":"47","author":"Palmisano","year":"2011","journal-title":"Annali Dell'Istituto Superiore Di Sanita"},{"issue":"2","key":"10.1016\/j.virusres.2024.199503_bib0028","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1432-1033.1996.00664.x","article-title":"Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus","volume":"241","author":"Powell","year":"1996","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.virusres.2024.199503_bib0029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/viro.1996.0528","article-title":"Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis","volume":"224","author":"Schn\u00f6lzer","year":"1996","journal-title":"Virology."},{"issue":"3","key":"10.1016\/j.virusres.2024.199503_bib0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2460\/ajvr.75.3.273","article-title":"Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells","volume":"75","author":"Schwartz","year":"2014","journal-title":"Am. J. Vet. Res."},{"issue":"1","key":"10.1016\/j.virusres.2024.199503_bib0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2020.0100","article-title":"An overview of human immunodeficiency virus-1 antiretroviral drugs: general principles and current status","volume":"53","author":"Shin","year":"2021","journal-title":"Infect. ChemOther"},{"issue":"4","key":"10.1016\/j.virusres.2024.199503_bib0032","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/34.4.589","article-title":"Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents","volume":"34","author":"Smyth","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.virusres.2024.199503_bib0033","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1128\/JVI.03208-12","article-title":"Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents","volume":"87","author":"Togami","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2024.199503_bib0034","first-page":"1239","article-title":"Sur la nature infectieuse de l'an\u00e9mie du cheval","volume":"139","author":"Vall\u00e9e","year":"1904","journal-title":"CR Acad. Sci."},{"issue":"10","key":"10.1016\/j.virusres.2024.199503_bib0035","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.3390\/v15101992","article-title":"Strategies in the design and development of non-nucleoside reverse transcriptase inhibitors (NNRTIs)","volume":"15","author":"Vanangamudi","year":"2023","journal-title":"Viruses."},{"key":"10.1016\/j.virusres.2024.199503_bib0036","unstructured":"WHO. 2022. \u2018HIV \u2013 number of people (All ages) living with HIV, https:\/\/Www.Who.Int\/Data\/Gho\/Data\/Indicators\/Indicator-Details\/GHO\/Estimated-Number-of-People\u2013Living-with-Hiv, (Accessed Apr. 19 2024)\u2019. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/estimated-number-of-people\u2013living-with-hiv."},{"issue":"21","key":"10.1016\/j.virusres.2024.199503_bib0037","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 Gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild","year":"1994","journal-title":"Proceed. Nation. Acad. Sci."},{"issue":"28","key":"10.1016\/j.virusres.2024.199503_bib0038","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1073\/pnas.0501560102","article-title":"A tumor necrosis factor receptor family protein serves as a cellular receptor for the macrophage-tropic equine lentivirus","volume":"102","author":"Zhang","year":"2005","journal-title":"Proceed. Nation. Acad. Sci."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170224001965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170224001965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:55:58Z","timestamp":1734504958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170224001965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"alternative-id":["S0168170224001965"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2024.199503","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy assessment of antiretroviral drugs against equine infectious anemia virus in vitro","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2024.199503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199503"}}